Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ischemia Reperfusion Injury-Pipeline Review, H1 2015

Ischemia Reperfusion Injury-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ischemia Reperfusion Injury-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ischemia Reperfusion Injury-Pipeline Review, H1 2015', provides an overview of the Ischemia Reperfusion Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Ischemia Reperfusion Injury Overview 8

Therapeutics Development 9

Pipeline Products for Ischemia Reperfusion Injury-Overview 9

Pipeline Products for Ischemia Reperfusion Injury-Comparative Analysis 10

Ischemia Reperfusion Injury-Therapeutics under Development by Companies 11

Ischemia Reperfusion Injury-Therapeutics under Investigation by Universities/Institutes 15

Ischemia Reperfusion Injury-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Ischemia Reperfusion Injury-Products under Development by Companies 20

Ischemia Reperfusion Injury-Products under Investigation by Universities/Institutes 23

Ischemia Reperfusion Injury-Companies Involved in Therapeutics Development 25

Adienne Pharma & Biotech 25

Alligator Bioscience AB 26

Antipodean Pharmaceuticals, Inc. 27

BioLineRx, Ltd. 28

Biomedica Management Corporation 29

Bolder Biotechnology, Inc. 30

Catalyst Biosciences, Inc. 31

Curatis Pharma GmbH 32

Gilead Sciences, Inc. 33

Ischemix 34

LG Life Sciences, Ltd. 35

Lotus Pharmaceutical Co., Ltd. 36

Mercury Pharmaceuticals, Inc. 37

Omeros Corporation 38

Opsona Therapeutics Ltd. 39

Peptinnovate Limited 40

Pharming Group N.V. 41

PledPharma AB 42

Prolong Pharmaceuticals 43

Proteo, Inc. 44

Prothix BV 45

Trophos SA 46

Zealand Pharma A/S 47

Zyrnat Biotherapeutics SL 48

Ischemia Reperfusion Injury-Therapeutics Assessment 49

Assessment by Monotherapy Products 49

Assessment by Target 50

Assessment by Mechanism of Action 53

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

ADC-1004-Drug Profile 60

AM/AMBP-1-Drug Profile 61

ANV-6L15-Drug Profile 64

APP-103-Drug Profile 65

BBT-030-Drug Profile 66

BBT-045-Drug Profile 67

BL-7060-Drug Profile 68

C1 esterase inhibitor (recombinant)-Drug Profile 70

CB-2782-Drug Profile 75

CMX-2043-Drug Profile 76

CRX-526-Drug Profile 78

Curaglutide-Drug Profile 79

danegaptide-Drug Profile 80

Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury-Drug Profile 81

Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders-Drug Profile 82

Elafin-Drug Profile 83

EP-80317-Drug Profile 86

Ergidina-Drug Profile 87

GS-459679-Drug Profile 88

KN-93-Drug Profile 89

KR-62980-Drug Profile 91

LSNTU-106-Drug Profile 92

mangafodipir-Drug Profile 93

MFH-244-Drug Profile 94

MG-53-Drug Profile 95

mirococept-Drug Profile 97

MitoQ-Drug Profile 99

Monoclonal Antibody for Ischemia Reperfusion Injury-Drug Profile 101

Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury-Drug Profile 102

Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury-Drug Profile 104

MTP-131-Drug Profile 105

NBD Peptide-Drug Profile 107

NecX-Drug Profile 109

Neutrolide-Drug Profile 110

NOXD-21-Drug Profile 111

Oligonucleotide for Oncology and Cardiovascular-Drug Profile 112

OMS-721-Drug Profile 113

OPN-305-Drug Profile 115

PAC-G31P-Drug Profile 117

Peptide to Activate AGTR1 for Cardiovascular, Metabolic Disorders, Immunology, Genito Urinary System And Sex Hormones-Drug Profile 119

PIN-201601-Drug Profile 121

PRO-02-Drug Profile 122

Protein for Ischemia/Reperfusion Injury-Drug Profile 123

R-190-Drug Profile 124

Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia-Drug Profile 126

Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury-Drug Profile 127

Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia-Drug Profile 128

Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury-Drug Profile 129

Sanguinate-Drug Profile 130

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury-Drug Profile 132

Small Molecules for Ischemia Reperfusion Injury-Drug Profile 133

Small Molecules for Ischemia Reperfusion Injury-Drug Profile 134

Small Molecules for Ischemia Reperfusion Injury and Inflammation-Drug Profile 135

Small Molecules to Activate AMPK for Ischemia Reperfusion Injury-Drug Profile 136

Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury-Drug Profile 137

Small Molecules to Inhibit PDE5 for Cardiovascular Disease-Drug Profile 138

SMTP-7-Drug Profile 139

Synthetic Peptides for Ischemia Reperfusion Injury-Drug Profile 140

Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders-Drug Profile 141

TRO-40303-Drug Profile 142

UCF-101-Drug Profile 144

UWA-TAT-Drug Profile 145

ZY-11-Drug Profile 146

Ischemia Reperfusion Injury-Recent Pipeline Updates 147

Ischemia Reperfusion Injury-Dormant Projects 165

Ischemia Reperfusion Injury-Discontinued Products 168

Ischemia Reperfusion Injury-Product Development Milestones 169

Featured News & Press Releases 169

Appendix 178

Methodology 178

Coverage 178

Secondary Research 178

Primary Research 178

Expert Panel Validation 178

Contact Us 178

Disclaimer 179

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H1 2015 14

Number of Products under Development for Ischemia Reperfusion Injury-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 29

Ischemia Reperfusion Injury-Pipeline by Adienne Pharma & Biotech, H1 2015 30

Ischemia Reperfusion Injury-Pipeline by Alligator Bioscience AB, H1 2015 31

Ischemia Reperfusion Injury-Pipeline by Antipodean Pharmaceuticals, Inc., H1 2015 32

Ischemia Reperfusion Injury-Pipeline by BioLineRx, Ltd., H1 2015 33

Ischemia Reperfusion Injury-Pipeline by Biomedica Management Corporation, H1 2015 34

Ischemia Reperfusion Injury-Pipeline by Bolder Biotechnology, Inc., H1 2015 35

Ischemia Reperfusion Injury-Pipeline by Catalyst Biosciences, Inc., H1 2015 36

Ischemia Reperfusion Injury-Pipeline by Curatis Pharma GmbH, H1 2015 37

Ischemia Reperfusion Injury-Pipeline by Gilead Sciences, Inc., H1 2015 38

Ischemia Reperfusion Injury-Pipeline by Ischemix, H1 2015 39

Ischemia Reperfusion Injury-Pipeline by LG Life Sciences, Ltd., H1 2015 40

Ischemia Reperfusion Injury-Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2015 41

Ischemia Reperfusion Injury-Pipeline by Mercury Pharmaceuticals, Inc., H1 2015 42

Ischemia Reperfusion Injury-Pipeline by Omeros Corporation, H1 2015 43

Ischemia Reperfusion Injury-Pipeline by Opsona Therapeutics Ltd., H1 2015 44

Ischemia Reperfusion Injury-Pipeline by Peptinnovate Limited, H1 2015 45

Ischemia Reperfusion Injury-Pipeline by Pharming Group N.V., H1 2015 46

Ischemia Reperfusion Injury-Pipeline by PledPharma AB, H1 2015 47

Ischemia Reperfusion Injury-Pipeline by Prolong Pharmaceuticals, H1 2015 48

Ischemia Reperfusion Injury-Pipeline by Proteo, Inc., H1 2015 49

Ischemia Reperfusion Injury-Pipeline by Prothix BV, H1 2015 50

Ischemia Reperfusion Injury-Pipeline by Trophos SA, H1 2015 51

Ischemia Reperfusion Injury-Pipeline by Zealand Pharma A/S, H1 2015 52

Ischemia Reperfusion Injury-Pipeline by Zyrnat Biotherapeutics SL, H1 2015 53

Assessment by Monotherapy Products, H1 2015 54

Number of Products by Stage and Target, H1 2015 56

Number of Products by Stage and Mechanism of Action, H1 2015 59

Number of Products by Stage and Route of Administration, H1 2015 62

Number of Products by Stage and Molecule Type, H1 2015 64

Ischemia Reperfusion Injury Therapeutics-Recent Pipeline Updates, H1 2015 152

Ischemia Reperfusion Injury-Dormant Projects, H1 2015 170

Ischemia Reperfusion Injury-Dormant Projects (Contd..1), H1 2015 171

Ischemia Reperfusion Injury-Dormant Projects (Contd..2), H1 2015 172

Ischemia Reperfusion Injury-Discontinued Products, H1 2015 173

List of Figures

Number of Products under Development for Ischemia Reperfusion Injury, H1 2015 14

Number of Products under Development for Ischemia Reperfusion Injury-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 54

Number of Products by Top 10 Targets, H1 2015 55

Number of Products by Stage and Top 10 Targets, H1 2015 55

Number of Products by Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Top 10 Routes of Administration, H1 2015 61

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 61

Number of Products by Top 10 Molecule Types, H1 2015 63

Number of Products by Stage and Top 10 Molecule Types, H1 2015 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adienne Pharma & Biotech

Alligator Bioscience AB

Antipodean Pharmaceuticals, Inc.

BioLineRx, Ltd.

Biomedica Management Corporation

Bolder Biotechnology, Inc.

Catalyst Biosciences, Inc.

Curatis Pharma GmbH

Gilead Sciences, Inc.

Ischemix

LG Life Sciences, Ltd.

Lotus Pharmaceutical Co., Ltd.

Mercury Pharmaceuticals, Inc.

Omeros Corporation

Opsona Therapeutics Ltd.

Peptinnovate Limited

Pharming Group N.V.

PledPharma AB

Prolong Pharmaceuticals

Proteo, Inc.

Prothix BV

Trophos SA

Zealand Pharma A/S

Zyrnat Biotherapeutics SL

Ischemia Reperfusion Injury Therapeutic Products under Development, Key Players in Ischemia Reperfusion Injury Therapeutics, Ischemia Reperfusion Injury Pipeline Overview, Ischemia Reperfusion Injury Pipeline, Ischemia Reperfusion Injury Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com